Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Stem Cells. Apr 26, 2014; 6(2): 82-93
Published online Apr 26, 2014. doi: 10.4252/wjsc.v6.i2.82
Published online Apr 26, 2014. doi: 10.4252/wjsc.v6.i2.82
Enhancing the efficacy of mesenchymal stem cell therapy
Michalis Mastri, Huey Lin, Techung Lee, Department of Biochemistry, University at Buffalo, Buffalo, NY 14214, United States
Michalis Mastri, Huey Lin, Techung Lee, Department of Biomedical Engineering, Center for Research in Cardiovascular Medicine, University at Buffalo, Buffalo, NY 14214, United States
Author contributions: Mastri M performed experiments and data analysis; Lin H performed experiments; Lee T contributed to data analysis and manuscript writing.
Supported by NIH, No. R01HL84590; NYSTEM; and University at Buffalo Biomedical Research Service Center
Correspondence to: Techung Lee, Associate Professor, Department of Biomedical Engineering, Center for Research in Cardiovascular Medicine, University at Buffalo, 140 Farber, 3435 Main Street, Buffalo, NY 14214, United States. chunglee@buffalo.edu
Telephone: +1-716-8293106 Fax: +1-716-8293106
Received: September 17, 2013
Revised: November 29, 2013
Accepted: January 13, 2014
Published online: April 26, 2014
Processing time: 220 Days and 9.3 Hours
Revised: November 29, 2013
Accepted: January 13, 2014
Published online: April 26, 2014
Processing time: 220 Days and 9.3 Hours
Abstract
Mesenchymal stem cell (MSC) therapy is entering a challenging phase after completion of many preclinical and clinical trials. Among the major hurdles encountered in MSC therapy are inconsistent stem cell potency, poor cell engraftment and survival, and age/disease-related host tissue impairment. The recognition that MSCs primarily mediate therapeutic benefits through paracrine mechanisms independent of cell differentiation provides a promising framework for enhancing stem cell potency and therapeutic benefits. Several MSC priming approaches are highlighted, which will likely allow us to harness the full potential of adult stem cells for their future routine clinical use.
Keywords: Mesenchymal stem cell; Therapy; Clinical trial; Paracrine